USA flag logo/image

An Official Website of the United States Government

DEVELOPMENT OF AMYGDALA SPECIFIC MONOCLONAL ANTIBODIES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61104
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
MH066458
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
PSYCHOGENICS, INC.
765 OLD SAW MILL RIVER RD TARRYTOWN, NY 10591-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: DEVELOPMENT OF AMYGDALA SPECIFIC MONOCLONAL ANTIBODIES
Agency: HHS
Contract: 1R43MH066458-01
Award Amount: $123,906.00
 

Abstract:

DESCRIPTION (provided by applicant): In this application we propose to use "Differential Immunization for Antigen and Antibody Discovery" (DIAAD) technology, a novel differential immunization method established by Vacold L.L.C., and generate rat monoclonal antibodies to epitopes specific to the Amygdala of mice. DIAAD is enabled by the Virtual Lymph Node (VLN), an implantable device used as a powerful immunological adjuvant with sensitivity to minute doses of antigen. The dose of antigen with which the VLN are loaded prior to implantation determines whether the immune reaction leads to a positive immune response, anergys or tolerance. The DIAAD technology is sensitive to antigens of broad chemical diversity, i.e., lipids, carbohydrate, gangliosides, proteins, and posttranslational protein modifications. Hence this technology allows us to tolerize the immune system against immuno-dominant and ubiquitously expressed epitopes and to direct the immune system towards less immunogenic but tissue specifically expressed antigens starting with complex mixtures of antigens. We chose the Amygdala as a target tissue since it is a central component of the structures, which consolidate and express emotions and has been implicated in the pathogenesis of affective mental disorders including depression. The possible importance of the Amygdala in the manifestation of affective mental disorders has been recognized for some time. Hence, there is a large scientific community both in the public and private sector, which devotes its resources to Amygdala research. One of the key objectives of the neuro-pharmaceutical industry is to develop novel therapeutics for the treatment of affective mental disorders. The specific aim of the proposed experiments is: to develop novel research tools for both applied and basic biomedical research in form of rat Monoclonal Antibodies (Moab's) against Amygdala specific epitopes of mice. The defined Milestone at the end of this phase 1 application is: to demonstrate the capacity to derive Amygdala specific MoAbs by differential tolerization /immunization using DIAAD and VLN technologies. These MoAbs should be usable for cytohistochemistry and/or western blot applications. We believe that these MoAbs will greatly accelerate research aimed to elucidate mechanisms of function of the Amygdala and will find widespread use in academic and industrial research. In a phase II extension of this application we wish to expand our portfolio of MoAbs reagents based on our results from phase I covering other important brain regions for human psychiatric diseases. In addition, we want to develop reagents to plastic changes of brain tissues in the context of inducible animal models with relevance to human psychiatric diseases.

Principal Investigator:

Andreas H. Kottmann
2127952360
ANDREAS.KOTTMANN@PSYCHOGENICS.COM

Business Contact:

Emer Leahy
9145930640
ANDREAS.KOTTMANN@PSYCHOGENICS.COM
Small Business Information at Submission:

PSYCHOGENICS, INC.
PSYCHOGENICS, INC. 4 SKYLINE DR HAWTHORNE, NY 10532

EIN/Tax ID: 134034631
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No